CMS also is proposing new policies for the Medicare Part D Drug Inflation Rebate Program as follows: Proposed 428.202(c)(3) provides that if a Part D rebatable drug first approved or licensed by the FDA on or before October 1, 2021, does not have AMP data reported under section 1927(b)(3) of the Act for any quarters during the period beginning on January 1, 2021 and ending on September 30, 2021, CMS would identify the payment amount benchmark period as the first calendar year, which would be no earlier than calendar year 2021, in which such drug has at least 1 quarter of AMP reported
The Civil Rights Act of 1964, Title VII : prohibits any discrimination by employers towards employees or job applicants on the basis of race, color, religion, sex, or national origin
Dent J Malays
You must be logged in to save this publication
Well continue to support research into the health consequences of this and other tobacco product trends that aim to appeal to a new generation of users.